SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin’s arm launches generic Aciphex Delayed-Release tablets, 20 mg in the US

11 Nov 2013 Evaluate

Lupin’s - US subsidiary, Lupin Pharmaceuticals, has launched its generic Rabeprazole Sodium delayed?release tablets, 20mg. The company had earlier received final approval from the US FDA for the same. Lupin’s Rabeprazole Sodium delayed?release tablets, 20mg, are the generic equivalent of Eisai Inc.’s Aciphex delayed?release tablets, 20mg, and are indicated for the treatment of Gastro esophageal reflux disease (GERD). Aciphex delayed?release tablets, 20mg, had annual U.S sales of approximately $ 864.3million (IMS MAT Jun 2013).

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×